CRISPR Therapeutics

Today at the @American_Heart Scientific Sessions, we presented data from our Phase 1b clinical trial evaluating CTX310, our investigational in vivo CRISPR/Cas9 gene editing therapy targeting ANGPTL3, in patients with severe hypertriglyceridemia: Details: bit.ly/48dq03x

Today, we shared updates on zugo-cel, our investigational allogeneic CAR-T cell therapy, in refractory rheumatologic autoimmune diseases. Promising data from the systemic sclerosis cohort were presented at @ACRheum. Details here: bit.ly/3Wx8a95 #ACR26

We're pleased to share that clinical data from our zugo-cel program in large B-cell lymphoma will be featured in an oral presentation at the @ASH_hematology Annual Meeting and Exposition, December 12-15 in New Orleans. Learn more here: bit.ly/4egFzuI

Today, we announced our third quarter earnings results. Read more about our recent highlights and outlook: bit.ly/4ir0PiA #CRSP

We’re excited to welcome Siva Sakhamuri, Ph.D. as Chief Technical Officer of @CRISPRTX. His 30+ years of technical operations & manufacturing leadership will be important as we advance our gene editing & RNA therapies into late-stage clinical development. bit.ly/4z6rAiQ